Skip to main content
Premium Trial:

Request an Annual Quote

Inverness Throws Down Gauntlet Again, Raises Bid for Biosite to $92.50 Per Share

NEW YORK (GenomeWeb News) - Biosite said today that it has received a revised merger offer from Inverness Medical Innovations of $92.50 per share, up from Inverness’ original offer of $90 per share.
 
The newest development in the proposed takeover of Biosite comes one week after Beckman Coulter matched Inverness’ $90 per-share bid.
 
Beckman had initially bid $85 per share for Biosite in late March.
 
Biosite said it is evaluating Inverness’ offer, which expires at 8 a.m. EDT, May 16. Inverness reserves the right to withdraw the offer, however, if, among other things, Biosite does not publicly state by the end of the business day today that Inverness' bid is superior to Beckman’s most recent offer.
 
 
Inverness also wants Biosite to stipulate that Beckman has until 11:59 PM EDT, May 15 to match its offer.
 
Beckman officials could not be reached for comment by press time.
The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.